Clinical Development


Sorafenib is an oral multiple kinase inhibitor that inhibits proteins involved in both tumor cell proliferation and angiogenesis, or the formation of new blood vessels that support the growth of cancer cells.  We are working with our partner Bayer to implement a clinical development program designed to assess sorafenib's applicability across multiple tumor types.